• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Azenta Life Sciences and Frontier Space Announce Strategic Partnership to Advance Space-Based Life Sciences Research Infrastructure

    2/9/26 4:05:00 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology
    Get the next $AZTA alert in real time by email

    BURLINGTON, Mass., Feb. 9, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced a strategic partnership with Frontier Space, a pioneer in commercial space-based research systems, to conduct cutting-edge scientific experiments in space. This collaboration aims to harness the unique benefits of the microgravity environment to accelerate discovery and innovation in life sciences, including participation in the recently launched EGGS-2 (Early Gen micro-Gravity Service) mission, developed in collaboration with Orbital Paradigm. The mission was intended to test and advance the performance of Frontier's SpaceLab Mk 2 research platform under real launch and spaceflight conditions.

    This collaboration provides a strategic opportunity for Azenta to demonstrate how its sample management technologies perform in demanding research environments, helping extend use of its high-precision consumables into new research settings and next-generation workflows, further reinforcing the company's leadership in sample integrity.

    Launched in January 2026, the mission included 42 passive experimental samples using FluidX™ 0.26mL tubes from Azenta Life Sciences that have been specially selected for their precision engineering, proven reliability, and durability under extreme conditions - qualities important for generating dependable data in space-based experiments. For this mission, the FluidX tubes are integrated into a custom-designed container created to safely secure and protect samples during launch and spaceflight operations.

    A key focus of the campaign was evaluating the platform's active thermal management capabilities, including systems designed to support temperature control and thermal cycling during spaceflight - capabilities that are essential for life sciences research in microgravity. In addition, thermal sensors built into the payload were intended to monitor temperature changes in real time, providing scientists with valuable data about how the space environment affects the samples. Conditions found in space can accelerate key biological processes and provide scientific insights not easily achievable on Earth, helping researchers to support faster scientific learning cycles and study phenomena that are difficult to replicate on Earth.

    Dr. Aqeel Shamsul, CEO, Frontier Space, commented: "SpaceLab Mk 2 is a critical demonstration of our technology's readiness for orbital operations. By verifying our systems in real space conditions, we're building confidence in our platform and enabling faster iteration of technology development. Working with trusted partners like Azenta, whose sample storage technology brings proven reliability and integrity to spaceflight conditions, is essential as we validate the foundations for future life sciences research in orbit. The success of EGGS-2 brings us closer to a future where pharmaceutical research and biomanufacturing beyond Earth become routine."

    Michael Bussmann, Vice President and General Manager, Consumables and Instruments at Azenta Life Sciences, said: "We are thrilled to see FluidX technology playing a key role in this important early-stage mission. Engineered to perform under the most demanding conditions – now including spaceflight – our sample storage tubes provide the reliability and integrity needed for experiments in microgravity. By supporting Frontier's SpaceLab platform during spaceflight testing, we are helping lay the foundation for future biological and pharmaceutical research studies conducted in space and supporting our customers as they explore emerging research environments and advance scientific understanding."

    This mission serves as an initial step in exploring how Azenta's trusted sample management technologies perform in emerging research environments. While early-stage in nature, the collaboration provides early technical insights and reinforces the reliability of Azenta's consumables across a wide range of applications in life sciences research.

    About Azenta Life Sciences

    Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.

    Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.

    About Frontier Space

    Frontier Space is a UK space biotech company building platform technology to unlock the potential of pharmaceutical in-space biomanufacturing and research and development for the emerging commercial space industry. The company's platform technologies, SpaceLab and XSB, aim to offer flexible, scalable infrastructure for pharmaceutical R&D and biomanufacturing in orbit. Learn more at www.frontier-space.co.uk.

    MEDIA CONTACT for Frontier Space

    Anjali Sanjay

    a.sanjay@frontier-space.co.uk

    MEDIA CONTACT for Azenta Life Sciences:

    Renay Picard

    renay.picard@azenta.com

    Director of Marketing, Sample Management Solutions

    INVESTOR CONTACT for Azenta Life Sciences:

    Yvonne Perron

    Vice President, Financial Planning & Analysis and Investor Relations

    ir@azenta.com

    Maria Isabel Cuartas

    ir@azenta.com

    Azenta logo (PRNewsfoto/Azenta)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/azenta-life-sciences-and-frontier-space-announce-strategic-partnership-to-advance-space-based-life-sciences-research-infrastructure-302682799.html

    SOURCE Azenta

    Get the next $AZTA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZTA

    DatePrice TargetRatingAnalyst
    1/5/2026$50.00In-line → Outperform
    Evercore ISI
    12/19/2025$42.00 → $44.00Buy
    Needham
    10/30/2025$38.00Hold → Buy
    Jefferies
    8/6/2025$35.00Mkt Perform → Outperform
    Raymond James
    7/22/2025$35.00Equal-Weight
    Stephens
    12/18/2024$50.00 → $60.00Equal-Weight → Overweight
    Stephens
    4/4/2024$64.00Hold
    Jefferies
    2/1/2024$61.00 → $79.00Buy
    B. Riley Securities
    More analyst ratings

    $AZTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Cornog William L bought $189,884 worth of Common (7,000 units at $27.13), increasing direct ownership by 37% to 25,795 units (SEC Form 4)

    4/A - Azenta, Inc. (0000933974) (Issuer)

    11/25/25 4:28:43 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Amendment: Director Malus Alan J bought $319,800 worth of Common (12,000 units at $26.65), increasing direct ownership by 238% to 17,035 units (SEC Form 4)

    4/A - Azenta, Inc. (0000933974) (Issuer)

    11/14/25 4:10:07 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Amendment: President and CEO Marotta John bought $25,990 worth of Common (1,000 units at $25.99), increasing direct ownership by 0.94% to 107,296 units (SEC Form 4)

    4/A - Azenta, Inc. (0000933974) (Issuer)

    11/14/25 4:10:08 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Azenta upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Azenta from In-line to Outperform and set a new price target of $50.00

    1/5/26 8:28:55 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Needham reiterated coverage on Azenta with a new price target

    Needham reiterated coverage of Azenta with a rating of Buy and set a new price target of $44.00 from $42.00 previously

    12/19/25 7:47:35 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta upgraded by Jefferies with a new price target

    Jefferies upgraded Azenta from Hold to Buy and set a new price target of $38.00

    10/30/25 7:56:09 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by Director Cornog William L

    4/A - Azenta, Inc. (0000933974) (Issuer)

    2/6/26 6:21:57 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Director Nova Tina Susan was granted 5,663 units of Common, increasing direct ownership by 56% to 15,772 units (SEC Form 4)

    4 - Azenta, Inc. (0000933974) (Issuer)

    2/6/26 6:12:14 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    SEC Form 4 filed by Director Cornog William L

    4 - Azenta, Inc. (0000933974) (Issuer)

    2/6/26 5:47:58 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $AZTA
    SEC Filings

    View All

    Azenta Life Sciences and Frontier Space Announce Strategic Partnership to Advance Space-Based Life Sciences Research Infrastructure

    BURLINGTON, Mass., Feb. 9, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced a strategic partnership with Frontier Space, a pioneer in commercial space-based research systems, to conduct cutting-edge scientific experiments in space. This collaboration aims to harness the unique benefits of the microgravity environment to accelerate discovery and innovation in life sciences, including participation in the recently launched EGGS-2 (Early Gen micro-Gravity Service) mission, developed in collaboration with Orbital Paradigm. The mission was intended to test and advance the performance of Frontier's SpaceLab Mk 2 research platform under real launch and spaceflight conditions. This co

    2/9/26 4:05:00 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta Reports First Quarter Results for Fiscal 2026, Ended December 31, 2025

    BURLINGTON, Mass., Feb. 4, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the first quarter ended December 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale and the entry into a definitive agreement to sell the business, which is expected to close on or before March 31, 2026. Quarter Ended Dollars in millions, except per share data December 31, September 30, December31, Change 2025 2025 2024 (1) Prior Qtr Prior Yr. Revenue from Continuing Operations $ 149 $ 159 $ 147 (7) % 1 % Organ

    2/4/26 6:30:00 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta Announces Fiscal 2026 First Quarter Conference Call and Webcast

    BURLINGTON, Mass., Jan. 21, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal first quarter 2026 earnings which ended on December 31, 2025, on Wednesday, February 4, 2026, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, February 4, 2026, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on February 5, 2026. About Azenta Life SciencesAzenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide

    1/21/26 4:05:00 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    SEC Form 10-Q filed by Azenta Inc.

    10-Q - Azenta, Inc. (0000933974) (Filer)

    2/5/26 4:09:16 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Azenta, Inc. (0000933974) (Filer)

    2/4/26 7:24:14 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta Inc. filed SEC Form 8-K: Leadership Update

    8-K - Azenta, Inc. (0000933974) (Filer)

    1/30/26 7:46:32 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Azenta Inc.

    SC 13G/A - Azenta, Inc. (0000933974) (Subject)

    11/13/24 4:05:02 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Amendment: SEC Form SC 13D/A filed by Azenta Inc.

    SC 13D/A - Azenta, Inc. (0000933974) (Subject)

    11/4/24 8:41:47 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    SEC Form SC 13G filed by Azenta Inc.

    SC 13G - Azenta, Inc. (0000933974) (Subject)

    10/31/24 11:55:02 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    Leadership Updates

    Live Leadership Updates

    View All

    Flex Set to Join S&P MidCap 400; Azenta and Concentra Group Holdings to Join S&P SmallCap 600

    NEW YORK, Nov. 19, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Flex Ltd (NASD: FLEX) will replace Azenta Inc. (NASD: AZTA) in the S&P MidCap 400, and Azenta will replace Envestnet Inc. (NYSE:ENV) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, November 25. Bain Capital is acquiring Envestnet in a deal expected to be completed soon, pending final closing conditions. Azenta's market capitalization is no longer representative of the mid-cap market space.Concentra Group Holdings Inc. (NYSE:CON) will replace Myers Industries Inc. (NYSE:MYE) in the S&P SmallCap 600 effective prior to the openin

    11/19/24 5:56:00 PM ET
    $AZTA
    $CON
    $ENV
    Industrial Machinery/Components
    Technology
    Medical Specialities
    Health Care

    Azenta Announces the Addition of Three New Independent Directors Effective Immediately and New Initiative to Drive Value

    William L. Cornog, Quentin Koffey and Alan J. Malus Add Deep Industry Expertise and Track Records of Shareholder Value Creation to the Board Establishes Value Creation Committee of the Board Comprised of New Directors, CEO John Marotta, and Current Director Martin Madaus Reaffirms Full-Year 2024 Financial Guidance BURLINGTON, Mass., Nov. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced the appointment of three new independent directors to its Board. William Cornog, former head of KKR Capstone, the portfolio operations team of KKR & Co., and Alan Malus, former Corporate Executive Vice President of Thermo Fisher, join as part of Azenta's ongoing i

    11/4/24 8:00:00 AM ET
    $AZTA
    $BV
    $LVWR
    Industrial Machinery/Components
    Technology
    Real Estate
    Motor Vehicles

    AZENTA ANNOUNCES APPOINTMENT OF JOHN P. MAROTTA AS CEO

    Succeeds Dr. Stephen Schwartz Following 14-Year Tenure BURLINGTON, Mass., Sept. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced that John P. Marotta will join the Company as President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz, who is retiring following a distinguished tenure. Dr. Schwartz will remain as an advisor to Azenta to ensure a smooth and successful transition.  Mr. Marotta has two decades of experience leading global companies in life sciences, medical devices, and diagnostics, and is joining Azenta from Patient Square Capital, a leading healthcare investment firm, where he serves as Executive in Residence. P

    9/4/24 8:00:00 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    Financials

    Live finance-specific insights

    View All

    Azenta Reports First Quarter Results for Fiscal 2026, Ended December 31, 2025

    BURLINGTON, Mass., Feb. 4, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the first quarter ended December 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale and the entry into a definitive agreement to sell the business, which is expected to close on or before March 31, 2026. Quarter Ended Dollars in millions, except per share data December 31, September 30, December31, Change 2025 2025 2024 (1) Prior Qtr Prior Yr. Revenue from Continuing Operations $ 149 $ 159 $ 147 (7) % 1 % Organ

    2/4/26 6:30:00 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta Announces Fiscal 2026 First Quarter Conference Call and Webcast

    BURLINGTON, Mass., Jan. 21, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal first quarter 2026 earnings which ended on December 31, 2025, on Wednesday, February 4, 2026, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, February 4, 2026, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on February 5, 2026. About Azenta Life SciencesAzenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide

    1/21/26 4:05:00 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta Reports Fourth Quarter and Full Year Fiscal 2025 Results, Ended September 30, 2025

    Q4'25 reported revenue growth of 6% year over year and 4% on an organic basisFY'25 reported revenue growth of 4% and 3% on an organic basisFY'25 Adjusted EBITDA margin expansion of 310 basis points versus last yearFY'26 organic revenue growth expected to be 3% to 5% year over year, with Adjusted EBITDA margin expansion of approximately 300 basis pointsBURLINGTON, Mass., Nov. 21, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the fourth quarter and fiscal year ended September 30, 2025. Quarter Ended Year Ended Dollars in millions, except per share data September 30, September 30, September 30, September 30, 2025 2024(1) Change 2025 2024(1) Change Revenue

    11/21/25 6:30:00 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology